Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

vaccine exports

- PMLiVE

Lilly announces plan for new $3bn facility to boost manufacturing in Europe

The facility will be built in the Netherlands and will increase capacity for the company's oral medicines portfolio

- PMLiVE

EU medicine shortages hit record highs in 2023 and 2024

Even with countermeasures in place, European auditors warn that the risks remain elevated

- PMLiVE

Lilly’s early Alzheimer’s disease treatment approved in the EU

Marketing authorisation follows positive late-stage trial results

ECA webinar image

ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs

On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation...

Genesis Research Group

- PMLiVE

Invivyd working with FDA towards potential Biologics License Application for COVID-19

The company plans head-to-head safety evaluation with COVID-19 vaccine, pending regulatory alignment

- PMLiVE

FDA approves Pfizer and BioNTech’s jab for COVID-19

Globally, five billion doses of the companies’ vaccine have been distributed

- PMLiVE

Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma

The drug is already approved in the EU across three other multiple myeloma indications

- PMLiVE

Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP

Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1

- PMLiVE

J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma

The drug is already approved in the EU to treat relapsed or refractory cases of the blood cancer

- PMLiVE

Johnson & Johnson’s Darzalex approved by EC as first treatment for high-risk SMM

The early precursor of active multiple myeloma accounts for around 15% of all new multiple myeloma cases

- PMLiVE

Roche’s Itovebi granted EC approval to treat advanced breast cancer patients

Hormone receptor-positive breast cancer accounts for around 70% of all breast cancer cases

EU flag

EC approves SpringWorks Therapeutics’ Ezmekly to treat rare genetic disorder NF1

Neurofibromatosis type 1 affects an estimated 135,000 people in the EU

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links